secwatch / observer
8-K filed February 20, 2024, 6:59 PM ET ticker HEPA CIK 0001583771
leadership confidence high sentiment neutral materiality 0.45

Chairman Gary Jacob resigns from Hepion board; John Brancaccio appointed Chairman

Hepion Pharmaceuticals, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Brancaccio

Chairman
HEPA · Hepion Pharmaceuticals, Inc.
Effective
2024-02-20
Filed
February 20, 2024, 6:59 PM ET
Dr. Jacob was Chairman of the Company and the Board of Directors appointed John Brancaccio as Chairman.
Departed

Gary Jacob

Chairman of the Board
HEPA · Hepion Pharmaceuticals, Inc.
Effective
2024-02-20
Successor
John Brancaccio
Filed
February 20, 2024, 6:59 PM ET
On February 20, 2024, Dr. Gary Jacob resigned from the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) for personal reasons.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Brancaccio was appointed as Chairman at Hepion Pharmaceuticals, Inc..

Action
appointed
Role
Chairman
Exact text from the filing
Dr. Jacob was Chairman of the Company and the Board of Directors appointed John Brancaccio as Chairman.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Jacob resigned as Chairman of the Board at Hepion Pharmaceuticals, Inc..

Action
resigned
Role
Chairman of the Board
Exact text from the filing
On February 20, 2024, Dr. Gary Jacob resigned from the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) for personal reasons.
View on SEC.gov

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-24-007222
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.